In the evolving landscape of healthcare professional (HCP) engagement, face-to-face interactions remain a cornerstone. They ...

NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...

A hole has been blown in Bausch Health's late-stage pipeline, after a follow-up to its top-selling drug product Xifaxan ...

Collectively, the 100 companies on the list generated revenues of £3.7 billion ($5.06 billion), rising by around £3 billion ...

A new technology elucidated yesterday in the journal Nature has the potential to be a leap forward in DNA synthesis, allowing ...

That is according to the Wall Street Journal, which has said MSD failed to reach an agreement with Revolution on a fair price for the business, which has a cancer-focused pipeline headed by ...

In this interview conducted during JPM Week in San Francisco, pharmaphorum Editor in Chief Jonah Comstock spoke with Adrian ...

The Bio-Hermes-002 study, involving 1,000 volunteers aged over 60 in the UK, US and Canada, is using finger-prick testing to ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce ...

Hopstem has already completed phase 1 testing of hNPC01 in China, with encouraging results, and says it has now reached ...

"The addition of relacorilant to nab-paclitaxel, a trusted and effective chemotherapy, is positioned to become a new standard ...